Athira Pharma Inc (ATHA)

Currency in USD
0.401
+0.003(+0.75%)
Closed·
0.4010.000(-0.03%)
·
ATHA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ATHA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.3900.411
52 wk Range
0.2203.670
Key Statistics
Prev. Close
0.398
Open
0.398
Day's Range
0.39-0.411
52 wk Range
0.22-3.67
Volume
83.85K
Average Volume (3m)
564.98K
1-Year Change
-86.59%
Book Value / Share
0.82
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATHA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.400
Downside
-0.25%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Athira Pharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Athira Pharma Inc Company Profile

Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Athira Pharma Inc SWOT Analysis


ALS Drug Promise
Athira Pharma's ATH-1105 shows potential in ALS treatment, with positive preclinical data and Phase 1 results driving future clinical plans
Financial Crossroads
Despite $37M cash reserves, Athira faces financial challenges. Market cap decline to $9.8M reflects investor caution amid strategic shifts
Strategic Pivot
Explore Athira's strategic review process and pursuit of partnerships to accelerate ATH-1105 development and enhance shareholder value
Market Sentiment
Analyst ratings hold at "Market Perform" without price targets, reflecting cautious optimism as Athira advances its focused ALS program
Read full SWOT analysis

Compare ATHA to Peers and Sector

Metrics to compare
ATHA
Peers
Sector
Relationship
P/E Ratio
−0.3x−4.2x−0.5x
PEG Ratio
−0.010.100.00
Price/Book
0.5x2.7x2.6x
Price / LTM Sales
-1.7x3.3x
Upside (Analyst Target)
−0.2%93.4%40.3%
Fair Value Upside
Unlock−9.2%5.1%Unlock

Analyst Ratings

0 Buy
3 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.400
(-0.25% Downside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.18 / -0.22
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ATHA Income Statement

People Also Watch

2.140
VOR
+8.08%
5.56
REPL
+3.93%
21.81
SRPT
+7.44%
14.9100
INKT
-2.68%
0.683
MBRX
+5.40%

FAQ

What Stock Exchange Does Athira Pharma Trade On?

Athira Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Athira Pharma?

The stock symbol for Athira Pharma is "ATHA."

What Is the Athira Pharma Market Cap?

As of today, Athira Pharma market cap is 15.80M.

What Is Athira Pharma's Earnings Per Share (TTM)?

The Athira Pharma EPS (TTM) is -1.54.

When Is the Next Athira Pharma Earnings Date?

Athira Pharma will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is ATHA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Athira Pharma Stock Split?

Athira Pharma has split 0 times.

How Many Employees Does Athira Pharma Have?

Athira Pharma has 26 employees.

What is the current trading status of Athira Pharma (ATHA)?

As of 16 Aug 2025, Athira Pharma (ATHA) is trading at a price of 0.40, with a previous close of 0.40. The stock has fluctuated within a day range of 0.39 to 0.41, while its 52-week range spans from 0.22 to 3.67.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.